Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Ewald Wöll; Josef Thaler; Felix Keil; Birgit Gruenberger; Michael Hejna; Wolfgang Eisterer; Michael A Fridrik; Hanno Ulmer; Vera Trommet; Florian Huemer; Lukas Weiss; Richard Greil

doi:10.21873/anticanres.11987

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Ewald Wöll, Josef Thaler, Felix Keil, Birgit Gruenberger, Michael Hejna, Wolfgang Eisterer, Michael A Fridrik, Hanno Ulmer, Vera Trommet, Florian Huemer (Co-author), Lukas Weiss (Co-author), Richard Greil (Last author)

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

9 Citations (Web of Science)

Original language	English
Pages (from-to)	5553-5558
Journal	ANTICANCER RESEARCH
Volume	37
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.11987
Publication status	Published - 2017

Keywords

MULTICENTER PHASE-II
MEDIKAMENTOSE TUMORTHERAPIE AGMT
1ST-LINE THERAPY
TRIAL
OXALIPLATIN
CHEMOTHERAPY
IRINOTECAN
CISPLATIN
PLUS
ADENOCARCINOMA

Access to Document

10.21873/anticanres.11987

Cite this

Wöll, E., Thaler, J., Keil, F., Gruenberger, B., Hejna, M., Eisterer, W., Fridrik, M. A., Ulmer, H., Trommet, V., Huemer, F., Weiss, L., & Greil, R. (2017). Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. ANTICANCER RESEARCH , 37(10), 5553-5558. https://doi.org/10.21873/anticanres.11987

Wöll, Ewald ; Thaler, Josef ; Keil, Felix et al. / Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. In: ANTICANCER RESEARCH 2017 ; Vol. 37, No. 10. pp. 5553-5558.

@article{9b13361725084a3a9a8a8ee82bd909c3,

title = "Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.",

keywords = "MULTICENTER PHASE-II, MEDIKAMENTOSE TUMORTHERAPIE AGMT, 1ST-LINE THERAPY, TRIAL, OXALIPLATIN, CHEMOTHERAPY, IRINOTECAN, CISPLATIN, PLUS, ADENOCARCINOMA",

author = "Ewald W{\"o}ll and Josef Thaler and Felix Keil and Birgit Gruenberger and Michael Hejna and Wolfgang Eisterer and Fridrik, {Michael A} and Hanno Ulmer and Vera Trommet and Florian Huemer and Lukas Weiss and Richard Greil",

note = "IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria ",

year = "2017",

doi = "10.21873/anticanres.11987",

language = "English",

volume = "37",

pages = "5553--5558",

journal = "ANTICANCER RESEARCH ",

issn = "0250-7005",

number = "10",

}

Wöll, E, Thaler, J, Keil, F, Gruenberger, B, Hejna, M, Eisterer, W, Fridrik, MA, Ulmer, H, Trommet, V, Huemer, F , Weiss, L & Greil, R 2017, 'Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.', ANTICANCER RESEARCH , vol. 37, no. 10, pp. 5553-5558. https://doi.org/10.21873/anticanres.11987

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. / Wöll, Ewald; Thaler, Josef; Keil, Felix et al.
In: ANTICANCER RESEARCH , Vol. 37, No. 10, 2017, p. 5553-5558.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

AU - Wöll, Ewald

AU - Thaler, Josef

AU - Keil, Felix

AU - Gruenberger, Birgit

AU - Hejna, Michael

AU - Eisterer, Wolfgang

AU - Fridrik, Michael A

AU - Ulmer, Hanno

AU - Trommet, Vera

AU - Huemer, Florian

AU - Weiss, Lukas

AU - Greil, Richard

N1 - IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria

PY - 2017

Y1 - 2017

KW - MULTICENTER PHASE-II

KW - MEDIKAMENTOSE TUMORTHERAPIE AGMT

KW - 1ST-LINE THERAPY

KW - TRIAL

KW - OXALIPLATIN

KW - CHEMOTHERAPY

KW - IRINOTECAN

KW - CISPLATIN

KW - PLUS

KW - ADENOCARCINOMA

U2 - 10.21873/anticanres.11987

DO - 10.21873/anticanres.11987

M3 - Original Article

C2 - 28982869

SN - 0250-7005

VL - 37

SP - 5553

EP - 5558

JO - ANTICANCER RESEARCH

JF - ANTICANCER RESEARCH

IS - 10

ER -

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W et al. Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. ANTICANCER RESEARCH . 2017;37(10):5553-5558. doi: 10.21873/anticanres.11987